Oral supplementation with 2-fucosyllactose significantly decreased the severity of colitis in IL-10−/− mice, reducing the expression of IL-1β and IL-6 and increasing TGF-β expression and expansion of the propionate-producing commensal Ruminococcus gnavus [84]. The gene discussed is IL10; the disease is colitis.